Hernández-Morales D E, Hernández-Zaccaro A E
Vargas Medical School, Universidad Central de Venezuela, Caracas, Venezuela.
Eur J Cancer Care (Engl). 2005 Jul;14(3):264-6. doi: 10.1111/j.1365-2354.2005.00567.x.
Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients. We carried out a prospective study to evaluate the effectiveness of liposomal doxorubicin (LD) in gastrointestinal KS patients as well as its differential clinical activity depending on the location of the lesions. The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS. They were treated with LD, 20 mg/m(2) every 21 days, for six cycles. Eleven (73%) of the patients obtained a complete response of the gastrointestinal KS lesions and four (27%) a partial response. Regarding cutaneous lesions, only two (13%) of the patients reached a complete response, six (40%) a partial response and seven (47%) stabilized their disease. By applying Fisher's test we found a significant difference (P < 0.00035) when comparing the effectiveness of LD in gastrointestinal lesions in relation to cutaneous lesions. We conclude that LD is more effective in gastrointestinal KS and can be recommended in patients in third world countries with extensive gastrointestinal lesions.
卡波西肉瘤（KS）在第三世界艾滋病患者中仍然是一种常见的肿瘤。我们进行了一项前瞻性研究，以评估脂质体阿霉素（LD）对胃肠道KS患者的疗效，以及根据病变部位的不同临床活性。该研究纳入了15名年龄在25至35岁之间（平均27岁）的男性艾滋病患者，他们有超过25处皮肤病变和广泛的胃肠道KS。他们接受LD治疗，每21天20mg/m²，共六个周期。11名（73%）患者的胃肠道KS病变获得完全缓解，4名（27%）部分缓解。关于皮肤病变，只有2名（13%）患者达到完全缓解，6名（40%）部分缓解，7名（47%）病情稳定。通过应用费舍尔检验，我们发现比较LD对胃肠道病变和皮肤病变的疗效时存在显著差异（P<0.00035）。我们得出结论，LD对胃肠道KS更有效，可推荐给第三世界国家有广泛胃肠道病变的患者。
